Immunization with different formulations of Mycobacterium tuberculosis antigen 85A induces immune responses with different specificity and protective efficacy  by Tchilian, Elma et al.
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To  test  the  relative  efﬁcacy  of  CD4  and  CD8T  cells  in mediating  protective  immunity  to  Mycobacterium
tuberculosis  (Mtb),  we  compared  three  immunization  regimes  designed  to induce  preferentially  each
subset.  BALB/c  mice  were  immunized  intranasally  (i.n.)  or parenterally  with  antigen  85A  either  in a
recombinant  Adenoviral  vector  (Ad85A),  as  recombinant  protein  (r85A)  or  as a set  of  overlapping  15mer
peptides  (p85A).  For  the  ﬁrst  time  we  show  that  i.n.  immunization  with  overlapping  85A synthetic  pep-
tides  as  well  as  Ad85A  or r85A  can  provide  protection  against  Mtb  challenge.  For  all  forms  of  the  antigen,
i.n.  induces  greater  protection  against  Mtb  challenge  than  parenteral  immunization.  Ad85A  induces  a  pre-
dominantly  CD8T  cell  response  against  the 85A70–78 epitope,  r85A  a  CD4  response  to 85A99–118 and  p85A
a  balanced  CD4/CD8  response  to  the  CD4  85A99–118 and CD8  85A145–152 epitopes.  Immune  responses  to
CD4  85A99–118 and  CD8  85A70–78 but  not  CD8  85A145–152 are  protective.  Although  Ad85A  induces  a  stronguberculosis response  to  the  protective  CD8  85A70–78 epitope,  we  could  not  induce  any  response  to  this epitope  by
peptide  immunization.  These  results  show  that  although  peptide  immunization  can  induce  protective
immunity  to Mtb  challenge,  it can  also  induce  a  response  to  a non-protective  epitope  in antigen  85A,
indicating  that  the speciﬁcity  of  an  immune  response  may  be more  important  for  protection  against  Mtb
than  its  magnitude.  These  ﬁndings  have  important  implications  for  the  application  of  such  vaccines  in
humans.. Introduction
Tuberculosis (TB) remains an important disease worldwide and
ew vaccines to replace or boost the protection afforded by the
xisting vaccine, Bacille Calmette Guérin (BCG), are much needed,
specially in view of the development and spread of multidrug
esistant strains of Mtb.  Members of the mycolyl transferase family
f Mtb  proteins, also called the antigen 85 complex, are amongst
he most prominent tuberculosis vaccine candidates [1] because
mmune responses to these antigens can be detected in the majority
f humans exposed to Mtb  [2]. Numerous studies have shown that
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immunization with antigen 85 complex proteins, using a variety of
vaccine platforms, can provide protection against Mtb  challenge in
animal models [1,3–6].
We  have used antigen 85A as a model vaccine antigen to explore
in mice how to induce protection against Mtb challenge and deﬁne
the features and mode of action of protective immune responses.
These experiments have shown that intranasal (i.n.) immuniza-
tion is a highly effective route of administration [6,7] inducing an
activated population of lung resident T cells that inhibit mycobac-
terial growth very early after Mtb  challenge, in contrast to the later
effect of parenteral immunization [6,8–11]. Furthermore, under
some circumstances mucosal and parenteral immunization can
have additive protective effects [6,10].
Although recent studies are beginning to deﬁne the characteris-
tics of protective pulmonary mucosal immune responses [12] and
need for pathogen associated molecular pattern signals for appro-
priate innate immune system activation [13,14], many questions
Open access under CC BY license.remain to be resolved, particularly the relative importance of CD4
and CD8T cells in protection against early mycobacterial growth
established by pulmonary immunization. In this study we com-
pare the protective efﬁcacy of immunization protocols designed
.
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o induce CD4 or CD8 biased or balanced CD4/8T cell responses to
he single Mtb  antigen, 85A. We  show that the CD4 response to
5A is protective but that CD8T cell responses may  be protective or
on-protective, depending on their epitope speciﬁcity.
.  Materials and methods
.1.  Mice and immunization
All  experiments were performed with 6–8 week old female
ALB/c mice (Harlan Orlac, Blackthorn, UK), were approved by the
nimal use ethical committee of Oxford University and complied
ith UK Home Ofﬁce guidelines. Mice were immunized as shown
n Fig. 1, with either recombinant human serotype 5 adenovirus
xpressing 85A (Ad85A) [9], recombinant 85A protein (r85A) or
ith 15mer peptides overlapping by 10 amino acids covering the
ntire protein sequence of antigen 85A (p85A) (Suppl. Table 1).
Supplementary  data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/j.vaccine.
013.07.040.
.1.1.  Ad85A
Mice  were immunized once with Ad85A. For i.n. immuniza-
ion, mice were anaesthetized with isoﬂurane/oxygen and 2 × 10 9
irus particles (vp) of Ad85A in 40 l of PBS was  administered with
 pipette divided between both nostrils. For intramuscular (i.m.)
mmunization 2 × 109 vp of Ad85A was administered in the hind
egs in a total volume of 50 l.
.1.2. r85A
Mice  were immunized three times at 2 week intervals with 2 g
85A protein (a kind gift from KLMC Franken and THM Ottenhoff)
repared as described previously [10,15]. For i.n. immunization
ice were anaesthetized with isoﬂurane/oxygen and 2 g r85A
as mixed with 2 g of cholera toxin (CT) (Sigma, UK) and pipet-
ed into the nostrils in a total volume of 40 l. Mice were also
mmunized subcutaneously (s.c.) with 2 g of r85A in 200 l of
onophosphoryl lipid A (MPL) (Sigma, UK).
.1.3. p85A
Mice  were immunized three times at 2 week intervals with
00 ng of each of the sixty-six 15mer peptides overlapping by 10
mino acids covering the entire sequence of antigen 85A (p85A)
s described for r85A. For immunization against CD4 85A99–118
 g of each of the four peptides covering the region contain-
ng the 99–118 epitope, ETFLTSELPGWLQAN, SELPGWLQANRHVKP,
LQANRHVKPTGSAV and RHVKPTGSAVVGLSM (peptides 29, 30,
1 and 32 in Suppl. Table 1), were administered with adjuvant i.n.
r s.c. as above.
For  immunization against CD8 85A70–78 1 g of each of the
hree peptides covering the region containing the 70–78 epitope
SGLSVVMPVGGQSS, VVMPVGGQSSFYSDW, GGQSSFYSDWYQPAC
peptides 22, 23 and 24 in Suppl. Table 1) were administered with
djuvant i.n. or i.m. as above.
For  immunization against CD8 85A145–152. 1 g each of the
wo peptides covering the region containing the 145–152 epitope,
HPQQFVYAGAMSGL and FVYAGAMSGLLDPSQ peptides (peptides
7 and 38 in Suppl. Table 1) were administered with adjuvant i.n.
r s.c. as above.
Mice  were also immunized either with all peptides except the
D4 85A99–118 region (all peptides without peptides 29, 30, 31 and
2), all peptides except the CD8 85A70–78 region (lacking peptides
2, 23 and 24) or without the CD8 85A145–152 region (lacking pep-
ides 37 and 38) or in combinations as in the text.1 (2013) 4624– 4631 4625
2.2. Isolation of lymphocytes from lungs and spleen
Lungs were perfused with PBS, cut into pieces and digested with
0.7 mg/ml  collagenase type I (Sigma) and 30 g/ml DNase I (Sigma)
for 45 min  at 37 ◦C. Digested fragments were crushed through a
cell strainer using a syringe plunger, washed, layered over Lym-
pholyte (Cederlane, Ontario, Canada) and centrifuged at 1000 × g
for 25 min. Interface cells were collected and washed. Spleens were
passed through a cell strainer using a syringe plunger, red blood
cells were removed with lysis buffer (Qiagen, Crawley, UK) and the
cells were washed.
2.3.  Flow cytometry
Cells  were cultured in Hepes buffered RPMI, 10% heat-
inactivated FCS, L-glutamine, penicillin and streptomycin for 6 h.
Cells from Ad85A immunized animals were stimulated for 6 h with
either sixty-six 15mer peptides overlapping by 10 amino acids
covering the 85A protein sequence or with pool of peptides con-
taining about 10 consecutive peptides or with 3 peptides (Peptide
Protein Research Ltd., Fareham, UK) encoding the dominant CD4
(Ag85A99–118aa TFLTSELPGWLQANRHVKPT) and CD8 (Ag85A70–78aa
MPVGGQSSF and Ag85A145–152aa YAGAMSGL) peptide epitopes [9]
(Peptide Protein Research Ltd). Each peptide was at 2 g/ml. After
2 h at 37 ◦C, Golgi Plug (BD Biosciences, Oxford, UK) was  added
according to the manufacturer’s instructions.
Cells were washed and incubated with CD16/CD32 mono-
clonal antibody to block Fc binding. Subsequently the cells were
stained for CD4 (RM4-5), CD8 (53-6.7) (BD Bioscience, Oxford,
UK), IFN (XMG1.2) (eBioscience, Hatﬁeld, UK) using the BD
Cytoﬁx/Cytoperm kit according to the manufacturer’s instructions.
Cells were run on a LSRII (BD Biosciences) and analyzed using
FlowJo software (Tree Star Inc., Ashland, Oregon, USA). For sim-
plicity IFN intracellular staining was used to detect the majority
of antigen speciﬁc CD4 and CD8T cells, since the experiments were
concerned with the speciﬁcity of the response to 85A and not its
quality.
2.4. Infection with Mtb  and determination of mycobacterial load
Five  to 7 mice were anesthetized with isoﬂurane/oxygen and
infected i.n. with Mtb (Erdman strain) in 40 l PBS. Lung CFU
were enumerated 24 h after challenge to determine the num-
ber of organisms deposited (∼200 CFU). Mice were sacriﬁced at
indicated times, the lungs and spleen homogenized and mycobac-
terial load determined by plating 10-fold serial dilutions of tissue
homogenates on Middlebrook 7H11 agar plates (E&O Laboratories
Ltd., Bonnybridge, UK). Colonies were counted after 3–4 weeks of
incubation at 37 ◦C in 5% CO2.
2.5.  Statistical analysis
Data  were analyzed using one-way ANOVA followed by Tukey’s
multiple comparison test.
3. Results
3.1. Immunization with 85A in three different vaccine platforms
is  more protective intranasally than parenterally
We ﬁrst examined protection against Mtb  challenge afforded by
antigen 85A administered either as Ad85A, r85A or p85A (Fig. 1).Mice  immunized with Ad85A i.n. or i.m., were challenged after
5 weeks and Mtb lung CFU assessed 4 weeks later. The lung
mycobacterial load is reduced by ∼0.6 log10 in Ad85A i.m. immu-
nized compared to naïve animals, while Ad85A i.n. mice show
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ig. 1. Experimental design. Horizontal lines indicate the time scale of the experim
n ∼1.3 log10 reduction (Fig. 2A). This is consistent with previ-
us observations showing superior protection of i.n. administered
d85A compared to parenteral routes [6,7].
To determine the protection afforded by r85A, BALB/c mice
ere immunized with r85A either i.n. or s.c. as shown in Fig. 1
nd challenged ﬁve weeks after the last immunization. Intranasal
mmunization with r85A decreases the mycobacterial load by
1.5 log10 compared to naive mice, while parenteral immuniza-
ion has an insigniﬁcant effect (Fig. 2B). Similar results are obtained
hen the mice are immunized with p85A. The i.n. immunized ani-
als show a signiﬁcantly reduced Mtb  load while s.c. immunization
as an insigniﬁcant effect (Fig. 2C). We  also immunized mice 3
imes with CT i.n. or MPL  s.c. and challenged them with Mtb. The
ycobacterial burden in these controls does not differ from that
ound in naive animals (data not shown).
Taken together these data show that the i.n. route of admin-
stration of Ad85A, rec85A or p85A, is more effective against Mtb
hallenge than parenteral immunization in BALB/c mice when CT
nd MPL  are used as the mucosal and parenteral adjuvants.
.2.  Speciﬁcity of the immune responses to 85A administered in
ifferent  vaccine platforms
The  same antigen was administered in all immunization plat-
orms and the outcome in terms of protection was  similar in
ll i.n. immunized mice. However, since Ad85A induces a pre-
ominantly CD8T cell [6,9,11] while recombinant proteins in
djuvant induce CD4T cell responses [5,16,17] and 15mer pep-
ides might induce both CD4 and 8 responses [18], we  investigated
he speciﬁcity of the immune responses to Ad85A, r85A and
85A.Peptide pools covering the whole sequence of antigen 85A pro-
ein were used to stimulate lung and spleen cells from immunized
ice for 6 h in vitro and intracellular staining for IFN was per-
ormed to detect the majority of antigen speciﬁc CD4 and CD8T9  wks 14 wks
nd the vertical bars show immunizations, Mtb  challenge and harvest for CFU assay.
cells  (data not shown). After identifying the response to a pool, the
exact sequence of the peptide was narrowed down using individual
15mer peptides overlapping by 10 amino acids. We  identiﬁed three
major immunodominant epitopes: CD4 85A99–118, CD8 85A70–78
and CD8 85A145–152 as previously shown for antigen 85A in H-
2d mice [19]. However the different vehicles induce very different
responses.
After Ad85A immunization most of the CD8 responding cells in
the lungs and spleen react to the dominant 85A70–78 epitope and a
smaller proportion to the 85A145–152 epitope. As previously shown
there is also a small but detectable CD4 response to the 85A99–118
epitope. While the administration of Ad85A i.n. induces marginally
stronger lung responses, the i.m. route induces stronger splenic CD8
85A145–152 and CD4 responses (Fig. 3A). In all ﬁgures, for simplic-
ity we  present only IFN data for CD4 and CD8 cells. When we
used staining for TNF slightly fewer antigens speciﬁc were detected
but the relative magnitude of responses to different epitopes was
unchanged, while IL-2 stained few CD8T cells but could be used to
detect CD4 antigen speciﬁc cells, giving similar results to IFN for
this subset (data not shown).
Administration  of r85A i.n. induces an ∼5% lung CD4  response
against 85A99–118 but hardly detectable CD8 responses and this
route induces larger responses not only in the lung but also in the
spleen (0.4%) compared to s.c. immunization (0.1%) (Fig. 3B). Min-
imal and inconsistent CD4 responses are also detected against the
85A141–156 (FVYAGAMSGLLDPSQ peptide 38), 85A178–193 (DMWG-
PKEDPAWQRND peptide 45) or 85A205–214 (GKLIANNTRVWVYCG
peptide  49) epitopes (data not shown), in accordance with previous
studies in BALB/c mice (Suppl. Table 1) [19].
Animals immunized i.n. with p85A generate strong lung
responses against the CD4 85A99–118 (∼23%) and CD8 85A145–152
(∼23%). Surprisingly no response to the CD8 85A70–78 epitope is
detected. As with the other two  regimes, i.n. immunization induces
a stronger lung response compared to the parenteral route. Further-
more p85A i.n. induces a larger splenic response (∼1% CD4 and 0.3%
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Fig. 2. Protective efﬁcacy of antigen 85A administered i.n. or parenterally. Unimmu-
nized,  i.n. or parenterally immunized BALB/c mice were challenged 5 weeks after
the last immunization with Mtb i.n. and after further 5 weeks sacriﬁced for enu-
meration of lung and spleen (not shown) Mtb CFU. (A) Ad85A was  administered i.n.
or i.m. without adjuvant. (B) r85A was administered i.n. with cholera toxin or s.c.
w
f
c
C
a
3
8
8
t
With MPL. (C) p85A were administered i.n. with cholera toxin or s.c. with MPL. Data
rom one of three experiments with 5 mice/group are shown. ***p < 0.001, *p < 0.05
ompared to naïve animals, one-way ANOVA with Tukey’s post test.
D8) compared to parenteral administration of p85A (∼0.1% CD4
nd 0.05% CD8) (Fig. 3C).
.3.  Protective efﬁcacy of CD4 85A99–118 and epitopes CD8
5A145–152 against Mtb  challengeSince p85A i.n. induces both strong CD4 85A99–118 and CD8
5A145–152 speciﬁc responses we wished to determine the con-
ribution of each of these epitope to protection against Mtb.
e therefore immunized mice with peptides covering the CD41 (2013) 4624– 4631 4627
85A99–118 or CD8 85A145–152 regions. In both cases the expected
immune responses, to CD4 85A99–118 or CD8 85A145–152 are induced
(Fig. 4A and B). The mice responding only to the CD4  85A99–118 epi-
tope are protected as well as those immunized with all peptides,
but strikingly, animals responding only to CD8 85A145–152 are not
(Fig. 4C). Additional immunizations with all peptides minus the CD4
85A99–118 or CD8 85A145–152 peptides conﬁrm that only an immune
response to the CD4 85A99–118 epitope confers protection (Fig. 4C).
Mice immunized with peptide pools lacking speciﬁc epitopes show
antigen speciﬁc response identical to those immunized only with
the CD4 85A99–118 or CD8 85A145–152 peptides (Fig. 4A and B).
No response to the CD8 85A70–78 epitope is detected in mice
immunized with all peptides (p85A Fig. 3) or with peptides cov-
ering only this epitope (either as overlapping 15mers or a 9mer).
Nor do mice immunized with all peptides without CD8145–152 or
all without CD8145–152 and CD4 85A99–118, make a CD8 85A70–78
response. Finally, although we could not induce detectable CD8
85A70–78 responses, we  still challenged these animals with Mtb and
they show no protection (data not shown).
3.4. Activation status of 85A speciﬁc T cells
Because protective local lung immunity is associated with the
presence of activated T cells in the lungs [8,9,11], we examined the
activation status of antigen speciﬁc lung and spleen lymphocytes in
immunized mice. Ad85A i.n. induces a higher proportion of effec-
tor (CD62L− CD127−) and effector memory (CD62L− CD127+) 85A
speciﬁc CD8 cells in the lung and spleen compared to p85A i.n.
(Fig. 5A and B). Most of the antigen speciﬁc lung CD4 cells after i.n.
immunization are effector memory phenotype (CD62L− CD44hi),
while in the spleen both effector and central memory (CD62L+
CD44lo) cells are seen, irrespective whether Ad85A, r85A or p85A
are used for immunization (Fig. 5C and D).
In all cases i.n. administration induces a more activated phe-
notype of lung and splenic 85A speciﬁc cells, compared to the
respective parenteral regime (data not shown).
Taken together the results demonstrate that the three delivery
platforms and routes of administration induce antigen speciﬁc cells
with different speciﬁcity and activation status.
4. Discussion
We  assessed the immunogenicity and protective efﬁcacy of Mtb
antigen 85A administered as Ad85A, adjuvanted r85A or adju-
vanted p85A and show that all formulations delivered i.n. reduce
the lung mycobacterial load, despite the induction of different T cell
subsets with differing epitope speciﬁcity. For the ﬁrst time we  show
that i.n. administration of overlapping synthetic peptides covering
the whole sequence of antigen 85A confers protection against Mtb
challenge. The data do not establish however, that r85A or p85A
are poor parenteral vaccines since it is possible that an improved
adjuvant, such as those used by others with recombinant proteins,
might improve the protection attained by parenteral immunization
[5,20].
In accordance with previous observations in BALB/C mice
[19,21], we ﬁnd that antigen 85A induces responses to three
immunodominant epitopes: I-Ed CD499–118, Ld CD870–78 and Kd
CD8145–152. Ad85A induces a predominantly CD8T cell response
mainly against the CD8 85A70–78 epitope, with minimal but
detectable CD8 85A145–152 and CD4 85A99–118 responses. As
expected, adjuvanted r85A induces a CD4 response against the
dominant I-Ed CD499–118 epitope, while p85A immunization
induces  both CD4 85A99–118 and CD8 85A145–152 responses. For all
regimes the antigen speciﬁc cells in the lung are more activated
compared to the spleen, with Ad85A inducing the most highly
4628 E.  Tchilian et al. / Vaccine 31 (2013) 4624– 4631
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Fig. 3. Speciﬁcity of immune responses to antigen 85A. Parenterally or i.n. immunized BALB/c mice were sacriﬁced 4 weeks after the last immunization and the proportion
of lung and spleen CD4 and CD8 lymphocytes producing IFN determined by intracellular cytokine staining after 6 h stimulation with the 85A99–118, 85A70–78 and 85A145–152
p minis
c least 5
a
t
m
i
C
u
oeptides. (A) Ad85A was  administered i.n. or i.m. without adjuvant. (B) r85A was ad
holera toxin or s.c. with MPL. Cells from 3 to 4 mice were assayed separately in at 
ctivated CD8 cells. These data demonstrate that irrespective of
he T cell subset, the presence of highly activated effector/effector
emory antigen speciﬁc cells at the site of infection may  limit Mtb
nfection.
Although p85A induces responses to both CD4 85A99–118 and
D8 85A145–152, immunization with the separate peptides allowed
s to determine their contribution to Mtb  protection and show that
nly the CD4 response is protective. This may  be because while CD4tered i.n. with cholera toxin or s.c. with MPL. (C) p85A were administered i.n. with
 experiments. Error bars show SD.
85A99–118 and CD8 85A70–78 are expressed and can be recognized
in Mtb infected cells, CD8 85A145–152 is not expressed. Because
responses to all three epitopes are induced by Ad85A (Fig. 3), all
three must be expressed in Ad85A infected cells and both the CD8
epitopes can also be detected in transfected P815 cells [22], imply-
ing that processing of antigen 85A may  be different in Mtb  infected
macrophages. Such changes in epitope expression in different cells
when different vaccine vectors are used, are not unknown; an
E. Tchilian et al. / Vaccine 31 (2013) 4624– 4631 4629
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Fig. 4. Immune responses and protection in peptide immunized mice.
Mice  were immunized i.n. with pools of 2–3 15-mer peptides covering the 85A99–118, 85A70–78 and 85A145–152 or peptide pools covering the whole 85A sequence from which
the  85A99–118 or 85A145–152 sequences had been removed, as indicated on the x axis. 4 weeks after the last immunization the proportion of lung (A) and spleen (B) CD4 and CD8
lymphocytes producing IFN was determined by intracellular cytokine staining after 6 h stimulation with the 85A99–118 and 85A145–152 peptides. Cells from 3–4 mice were
a d with
( *p < 0.
e
e
r
t
p
i
r
i
pssayed separately. Error bars show SD. Similarly immunized mice were challenge
C). Data from one of two experiments with 5 mice/group are shown. ***p < 0.001, *
xtreme example is the recent ﬁnding of MHC  class II restricted
pitopes recognized by CD8T cells in Macaques immunized with a
ecombinant rhCMV vector [23].
Another example of changed epitope recognition in a mycobac-
erial antigen after different immunizations has been described
reviously in C57Bl/6 mice [16]. An adenoviral construct express-
ng an Ag85B/ESAT6 fusion gene induced a strong CD8 immune
esponse to the ESAT615–29 epitope but no protection. In contrast,
mmunization with IC31-adjuvanted recombinant protein induced
rimarily a CD4 response targeted to the Ag85B241–255 epitope Mtb ﬁve weeks after the last immunization and lung and spleen CFU enumerated
01 compared to naïve animals, one-way ANOVA with Tukey’s post test.
and  efﬁcient protection against Mtb  infection. This result too, was
ascribed to lack of expression of the ESAT615–29 epitope during Mtb
infection.
An alternative explanation might be that because CD8
85A145–152 speciﬁc cells induced by peptide immunization are less
activated than those induced by Ad85A (Fig. 5C and D), they are
unable to mediate protection. Furthermore, CD8 85A145–152 on its
own without CD4 help might induce defective CD8 memory cells
[24,25] although clearly 85A145–152 speciﬁc cells efﬁciently produce
IFN (and TNF, not shown) in response to antigen (Fig. 3).
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Fig. 5. Activation status of antigen speciﬁc CD4 and CD8T cells. Mice were sacriﬁced 4 weeks after the last i.n. immunization with Ad85A, r85A or p85A and after 6 h stimulation
of lung and spleen with 15mer peptides covering the 85A99–118, 85A70–78 and 85A145–152 sequences, the activation status of CD8T cells producing IFN was determined by
staining with CD62L and CD127 (A and B) and that of CD4T cells producing IL-2 by staining with CD62L and CD44 (C and D). The proportions of central (CD62L+ CD127+)
o c CD8
P 4hi) m
(  SD. 
a
n
A
8
u
t
i
t
i
s
a
C
i
c
[
C
8
8
i
m
c
a
n
b
mr effector (CD62L− CD127+) memory or effector (CD62L− CD127−) antigen speciﬁ
roportions of lung and spleen central (CD62L+ CD44lo) and effector (CD62L− CD4
C)  and (D), respectively. Cells from 4 mice were assayed separately. Error bars show
A further puzzle in these experiments is why we  cannot induce
n immune response to the CD8 85A70–78 epitope by peptide immu-
ization, while this is the dominant epitope detected following
d85A administration and after DNA vaccination [22]. Since CD8
5A70–78 is an Ld and CD8 85A145–152 is a Kd epitope [19] it seems
nlikely  that competition of peptides for MHC  class I binding, is
he explanation. Furthermore responses to both epitopes are seen
n Ad85A immunized (Fig. 3) or DNA immunized mice [22]. Never-
heless, even when CD8 85A145–152 is removed from the peptide
mmunization mix  there is still no response to 85A70–78. It also
eems unlikely that the lack of response is due to lack of CD4 help,
s we tried immunizing with a mixture of the CD8 85A70–78 and
D4 85A99–118 epitopes.
Interestingly a longer peptide covering the sequence 141–160,
n which the CD8 85A145–152. epitope is located, can stimulate
ytokine secretion from both CD8 and CD4 cells as shown by others
19] and sporadically in our experiments. The presence of a cryptic
D4 epitope might contribute to the powerful response to the CD8
5A145–152 epitope during peptide immunization. As this region of
5A is recognized by T cells from 90% of Mtb  infected humans [2],
t may  also be among the conserved epitopes, responses to which
ay beneﬁt Mtb  rather than the host [26].
In the light of the recent failure of the parenteral booster vac-
ine MVA85A to improve protection against tuberculosis over BCG
lone, new vaccine strategies are urgently needed [27]. Immu-
ization via the respiratory tract is promising. BCG administered
y this route is protective in mice, guinea pigs, cows and pri-
ates [10,28–30] and subunit vaccines are protective in mice [4,6]T cells after Ad85A and p85A immunization are shown for lung (A) and spleen (B).
emory antigen speciﬁc CD4T cells after different i.n. immunizations are shown in
Representative data from one of three experiments are shown.
and  immunogenic in primates [31]. Peptides with an appropriate
adjuvant offer a possible alternative formulation for respiratory
administration, with the advantage that immunogenic epitopes
can be selected and non-protective ones omitted from the vac-
cine. However, as shown here, some protective epitopes are not
immunogenic when given as peptides. Much further work will
be required to identify effective adjuvants that might be used in
humans and to investigate the duration of protection after peptide
immunization.
5. Conclusions
The three vaccines Ad85A, r85A and p85A are all protective
when given i.n. but induce different T cell responses. Reponses to
the CD4 85A99–118 and CD8 85A70–78, but not the CD8 85A145–152
epitope are protective. Peptide immunization did not induce an
immune response to the protective CD8 85A70–78 epitope. These
data have important implications for subunit vaccine design and
show that the exact speciﬁcity of the T cell response to a vaccine
antigen may  be more important than its magnitude. It remains to
be seen whether under other circumstances non-protective CD4
responses may  be induced.Acknowledgement
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